The presence or absence of TMMs segregated liposarcoma patients into distinct prognostic subsets (Figure 5): in fact, 9-year probability of survival was 75% for the 9 patients with ALT−/Tel− tumours, 51% for the 8 patients with telomerase-positive tumours and only 25% for the 10 patients with ALT-positive tumours. This evidence concerns the gene GPT and liposarcoma.